1. Biological autoimmunity screening in hepatitis C patients by anti-HepG2 lysate and anti-heat shock protein 70.1 autoantibodies.
- Author
-
Chumpitazi BF, Bouillet L, Drouet MT, Kuhn L, Garin J, Zarski JP, and Drouet C
- Subjects
- Adolescent, Adult, Aged, Autoantibodies blood, Cell Line, Child, Child, Preschool, Female, Humans, Male, Middle Aged, Molecular Chaperones immunology, ROC Curve, Sensitivity and Specificity, Statistics, Nonparametric, Autoantibodies immunology, Autoimmunity, Glucose Transporter Type 1 immunology, HSP70 Heat-Shock Proteins immunology, Hepatitis C, Chronic immunology
- Abstract
Viruses require viral and cellular chaperones during their life cycle and interactions of these molecules with the immune system are probable during the infection. Thus, an anti-chaperone antibody response has been firstly investigated in hepatitis C patients in this paper. A HepG2-lysate antigen (90, 79, 72, 70, 62, 54 and 48 kDa) was assayed in sera from 59 (19F/40M) chronic hepatitis C patients without cirrhosis before therapy. Forty of them were positive for anti-HepG2 lysate antigen antibodies and this test may evaluate biological autoimmunity. Hsp70.1, Hsp90 and calreticulin levels were significantly higher in this antigen than in a control HepG2 antigen. Secondly, Hsp70.1 was identified as Hsp 70 kDa protein-1 by proteomic analysis and studied as a possible antibody target. Fourteen out of 59 patients were positive for anti-Hsp70.1 antibodies that were inversely correlated with alanine aminotransferase levels, the Metavir activity index and viraemia. Finally, for comparative purposes, 50 sera from systemic lupus erythematosus (SLE) patients have been tested: eight and 41 of them were positive for anti-Hsp70.1 and anti-HepG2 lysate antigen antibodies, respectively. Therefore, anti-Hsp70.1 autoantibodies may be produced and can partially lead to biological autoimmunity in chronic hepatitis C patients.
- Published
- 2009
- Full Text
- View/download PDF